Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Zacks: Analysts Expect Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Will Post Earnings of -$1.49 Per Share

researchsnappy by researchsnappy
January 4, 2020
in Healthcare Research
0
Zacks: Analysts Expect Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Will Post Earnings of -$1.49 Per Share
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Tonix Pharmaceuticals logoEquities analysts expect that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will post ($1.49) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Tonix Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.75) and the highest is ($1.23). Tonix Pharmaceuticals posted earnings per share of ($61.00) during the same quarter last year, which suggests a positive year over year growth rate of 97.6%. The business is expected to report its next quarterly earnings report on Monday, March 16th.

On average, analysts expect that Tonix Pharmaceuticals will report full-year earnings of ($15.55) per share for the current financial year, with EPS estimates ranging from ($17.09) to ($14.01). For the next year, analysts forecast that the company will report earnings of ($2.30) per share, with EPS estimates ranging from ($2.49) to ($2.10). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that that provide coverage for Tonix Pharmaceuticals.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Friday, November 8th. The company reported ($5.69) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($4.35) by ($1.34).

Separately, ValuEngine downgraded shares of Tonix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th.

NASDAQ:TNXP traded down $0.01 during midday trading on Monday, hitting $1.26. The company’s stock had a trading volume of 640,305 shares, compared to its average volume of 2,710,753. Tonix Pharmaceuticals has a fifty-two week low of $0.86 and a fifty-two week high of $42.00. The firm’s 50 day moving average is $1.19 and its 200-day moving average is $0.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.88 and a quick ratio of 4.88. The firm has a market cap of $7.83 million, a P/E ratio of 0.00 and a beta of 1.03.

A number of large investors have recently modified their holdings of TNXP. Vanguard Group Inc. acquired a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $117,000. Acadian Asset Management LLC increased its holdings in Tonix Pharmaceuticals by 620.0% in the 2nd quarter. Acadian Asset Management LLC now owns 65,632 shares of the company’s stock worth $89,000 after buying an additional 56,516 shares during the period. Finally, A.R.T. Advisors LLC acquired a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $42,000. Institutional investors own 8.99% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer’s disease.

Featured Article: What is the Beige Book?

Get a free copy of the Zacks research report on Tonix Pharmaceuticals (TNXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com



Receive News & Ratings for Tonix Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Using competing risk and multistate model to estimate the impact of nosocomial infection on length of stay and mortality in burn patients in Southeast China.

Next Post

Why Is The U.S. Military Funding This New Biofuel Breakthrough?

Next Post
Why Is The U.S. Military Funding This New Biofuel Breakthrough?

Why Is The U.S. Military Funding This New Biofuel Breakthrough?

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News

Pa. Republicans reconsider Pitt funding over fetal tissue research, college voucher program

Arthur Pharma Closes Series A Financing Round

YouTube and the Achilles Tendon: An Analysis of Internet Information Reliability and Content Quality

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2022 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2022 researchsnappy.com